

# Discovery of novel PIP5K1a inhibitors as lead compounds for mCRPC therapy



ONCOLOGY	Lead
Product Type	Targeted Therapy Drugs
Indication	Prostate Cancer
Target	metastatic Castration-resistant prostate cancer (mCRPC)
MoA(Mechanism of Action)	PIP5K1 $\alpha$ inhibition
Competitiveness	<p>1) First-In-class : For the novel target PIP5K1<math>\alpha</math>, Kd value of T1522 is 21 nM which is the best among the PIP5K1<math>\alpha</math> inhibitors that can be searched around the world.</p> <p>2) Overcoming drug resistance : Differentiation from existing AKT target drugs under development in Phase 1/2 clinical trials that can overcome the drug resistance problem of mCRPC by simultaneously inhibiting the action of PI3K/ AKT and TP53GOF mutations.</p>
Development Stage	Lead
Route of Administration	Oral or Intravenous administration